Cargando…

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer deaths. Erlotinib is the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), the National Comprehensive Cancer Network (NCCN) guidelines recommend it as a first-line agent in patients with sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Hu, Tian, Xu, Zeng, Xian-Tao, Zhang, Yu, Wang, Yi, Wang, Fei, Zhou, Jian-Guo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718287/ https://www.ncbi.nlm.nih.gov/pubmed/26765461 http://dx.doi.org/10.1097/MD.0000000000002495

Ejemplares similares

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016)

The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
por: Chen, Yu Jie, et al.
Publicado: (2015)

The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis
por: Zhou, Jian-Guo, et al.
Publicado: (2015)

Prognostic value of platelet-to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis
por: Long, Yuming, et al.
Publicado: (2021)

Menopausal status and the risk of lung cancer in women: A PRISMA-compliant meta-analysis
por: Min, Lingfeng, et al.
Publicado: (2017)

Long-Term Coffee Consumption and Risk of Gastric Cancer: A PRISMA-Compliant Dose–Response Meta-Analysis of Prospective Cohort Studies
por: Zeng, Shao-Bo, et al.
Publicado: (2015)

The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
por: Shi, Zuolin, et al.
Publicado: (2022)

The Effect of Diabetes Mellitus on Lung Cancer Prognosis: A PRISMA-compliant Meta-analysis of Cohort Studies
por: Zhu, Linhai, et al.
Publicado: (2016)

Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis
por: Chen, Xiao-Dong, et al.
Publicado: (2016)

Prognostic value of MSI2 expression in human malignancies: A PRISMA-compliant meta-analysis
por: Wu, Wei, et al.
Publicado: (2022)

No association of TNF-α-308G/A polymorphisms with head and neck cancer risk: A PRISMA-compliant meta-analysis
por: Yuan, Cheng, et al.
Publicado: (2017)

The association between polymorphisms in the PDCD1 gene and the risk of cancer: A PRISMA-compliant meta-analysis
por: Zhang, Jie, et al.
Publicado: (2016)

The prognostic and clinicopathological significance of RBM3 in the survival of patients with tumor: A Prisma-compliant meta-analysis
por: Gao, Guangyu, et al.
Publicado: (2020)

Comparison of breast-conserving surgery with mastectomy in locally advanced breast cancer after good response to neoadjuvant chemotherapy: A PRISMA-compliant systematic review and meta-analysis
por: Sun, Yixuan, et al.
Publicado: (2017)

Low expression of nm23-H1 associates with poor survival of nasopharyngeal carcinoma patients: A prisma-compliant meta-analysis
por: Yuan, Cheng, et al.
Publicado: (2017)

Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review
por: Liu, Wei, et al.
Publicado: (2016)

Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
por: Zhang, Zongxin, et al.
Publicado: (2017)

Association between the risk of hepatitis virus-related hepatocellular carcinoma and EGF polymorphism: A PRISMA-compliant updated meta-analysis
por: Wang, Qinjing, et al.
Publicado: (2022)

Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis
por: Zhang, Dan, et al.
Publicado: (2018)

Association between the polymorphisms in XPG gene and gastric cancer susceptibility in Chinese populations: A PRISMA-compliant meta-analysis
por: Xia, Jun, et al.
Publicado: (2017)

Comparative effectiveness of prostate cancer treatments for patient-centered outcomes: A systematic review and meta-analysis (PRISMA Compliant)
por: Jayadevappa, Ravishankar, et al.
Publicado: (2017)

Diagnostic value of exosome derived long noncoding RNA in gastric cancer in Chinese population: A PRISMA-compliant systematic review and meta-analysis
por: Zhu, Kangle, et al.
Publicado: (2021)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis
por: Qixing, Mao, et al.
Publicado: (2015)

Effect of vitamin B supplementation on cancer incidence, death due to cancer, and total mortality: A PRISMA-compliant cumulative meta-analysis of randomized controlled trials
por: Zhang, Sui-Liang, et al.
Publicado: (2016)

Association of cytotoxic T lymphocyte-associated protein 4 gene -1772T/C polymorphism with gastric cancer risk: A prisma-compliant meta-analysis
por: Zhuo, Chenyi, et al.
Publicado: (2020)

Twice-daily vs higher-dose once-daily thoracic radiotherapy for limited-disease small-cell lung cancer: A PRISMA-compliant meta-analysis
por: Yang, Lin, et al.
Publicado: (2020)

Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy: A PRISMA-Compliant Systematic Review and Meta-Analysis
por: Zhang, Yuyu, et al.
Publicado: (2016)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Significant association between long non-coding RNA H19 polymorphisms and cancer susceptibility: A PRISMA-compliant meta-analysis and bioinformatics prediction
por: Li, Wei, et al.
Publicado: (2020)

SNF2 histone linker PHD RING helicase related Has_circ_0001649 as a diagnostic and prognostic biomarker in solid cancer: A PRISMA-compliant meta-analysis based on the Chinese population
por: Tian, Guangwei, et al.
Publicado: (2019)

The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis
por: Luo, Hui, et al.
Publicado: (2017)

Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized controlled trials
por: Deng, Huan, et al.
Publicado: (2020)

S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: A PRISMA-compliant meta-analysis and systematic review
por: Zhou, Shunkai, et al.
Publicado: (2020)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_u5v3ntr37i50tm05d3nlvc30rl